We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+13.24%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.44B
AUM Growth
-$133M
Cap. Flow
-$77.2M
Cap. Flow %
-3.16%
Top 10 Hldgs %
50.14%
Holding
73
New
3
Increased
9
Reduced
33
Closed
4

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$44.6M
2
PRME icon
Prime Medicine
PRME
+$39.9M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34.8M
4
REPL icon
Replimune Group
REPL
+$24.7M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$23.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$49.2M
2
PRTA icon
Prothena Corp
PRTA
+$31.9M
3
ONEM
1Life Healthcare
ONEM
+$29.7M
4
SKIN icon
SkinHealth Systems
SKIN
+$24.9M
5
LIVN icon
LivaNova
LIVN
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 99.08%
2 Industrials 0.92%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$247M 10.11%
20,249,789
-1,469,402
-7% -$16.5M
KRYS icon
2
Krystal Biotech
KRYS
$10.4B
$150M 6.15%
1,896,645
-2,900
-0.2% -$215K
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$144M 5.9%
2,632,912
+1,041,827
+65% +$44.6M
REPL icon
4
Replimune Group
REPL
$1.46B
$131M 5.38%
4,831,709
+1,186,400
+33% +$24.7M
FATE icon
5
Fate Therapeutics
FATE
$291M
$131M 5.35%
12,957,222
– –
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$96.4M 3.94%
4,502,111
+1,102,211
+32% +$23.5M
XENE icon
7
Xenon Pharmaceuticals
XENE
$5.81B
$93.1M 3.81%
2,360,414
-10,200
-0.4% -$371K
CLDX icon
8
Celldex Therapeutics
CLDX
$3.07B
$88.1M 3.61%
1,977,451
-7,700
-0.4% -$275K
PLRX icon
9
Pliant Therapeutics
PLRX
$68.7M
$75M 3.07%
3,878,599
-629,605
-14% -$13.2M
BEAM icon
10
Beam Therapeutics
BEAM
$3.03B
$69.2M 2.83%
1,770,587
-2,400
-0.1% -$107K
KYMR icon
11
Kymera Therapeutics
KYMR
$9.82B
$66.7M 2.73%
2,673,837
-202,800
-7% -$5.41M
LIVN icon
12
LivaNova
LIVN
$4.43B
$61.4M 2.51%
1,106,409
-429,953
-28% -$22M
DCPH
13
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$58.9M 2.41%
3,593,317
+620,288
+21% +$10.1M
IGMS
14
DELISTED
IGM Biosciences
IGMS
$56.7M 2.32%
3,334,355
– –
ARGX icon
15
argenx
ARGX
$64B
$56.3M 2.3%
148,517
-131,509
-47% -$49.2M
JAZZ icon
16
Jazz Pharmaceuticals
JAZZ
$15.9B
$50.8M 2.08%
318,945
+237,481
+292% +$34.8M
PEN icon
17
Penumbra
PEN
$12.7B
$49.3M 2.02%
221,809
+43,017
+24% +$8.41M
ZYME icon
18
Zymeworks
ZYME
$2.02B
$48.5M 1.99%
6,175,918
+410,100
+7% +$2.88M
RGNX icon
19
Regenxbio
RGNX
$638M
$43.4M 1.78%
1,913,512
-3,700
-0.2% -$83.6K
IMGN
20
DELISTED
Immunogen Inc
IMGN
$42.3M 1.73%
8,532,817
-15,328
-0.2% -$83.1K
PRME icon
21
Prime Medicine
PRME
$655M
$41M 1.68%
+2,209,350
New +$39.9M
RPTX
22
DELISTED
Repare Therapeutics
RPTX
$39.5M 1.62%
2,684,396
– –
ONEM
23
DELISTED
1Life Healthcare
ONEM
$38.9M 1.59%
2,326,625
-1,761,000
-43% -$29.7M
NRIX icon
24
Nurix Therapeutics
NRIX
$2.72B
$32.9M 1.35%
3,000,784
-5,900
-0.2% -$71.2K
OSH
25
DELISTED
Oak Street Health, Inc.
OSH
$30.6M 1.25%
1,420,617
+359,322
+34% +$7.52M
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2022 Portfolio in Review

As of Q4 2022, Redmile Group held 73 positions worth $2.44B, down 5.2% from $2.58B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Redmile Group withdrew a net $77.2M in Q4 2022, closing 4 positions and reducing 33 holdings. Its most notable exit was Prothena Corp, an estimated $31.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Redmile Group opened a new position in Prime Medicine worth $41M.

  • Redmile Group's largest Q4 2022 buy was Prime Medicine: 2,209,350 shares worth $41M.
  • Redmile Group added most to Akero Therapeutics in Q4 2022, an estimated $44.6M increase.
  • Redmile Group's biggest Q4 2022 reduction was argenx, cutting an estimated $49.2M.
  • Redmile Group fully exited Prothena Corp in Q4 2022, selling an estimated $31.9M.
  • Redmile Group's ten largest holdings make up 50% of its $2.44B portfolio in Q4 2022.
  • Redmile Group opened 3 new positions and closed 4 in Q4 2022.
  • Redmile Group's portfolio value fell 5.2% quarter-over-quarter to $2.44B.

Based on Redmile Group's 13F filing for Q4 2022, filed 14 Feb 2023.